Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.33 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.33 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.33 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9700185 | 1.00 | HRH4 (0.43) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| Hydrochloric Acid SCHEMBL4609656 | 1.00 | HRH4 (0.43) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| Hydrochloric Acid SCHEMBL7111958 | 1.00 | HRH4 (0.43) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| SCHEMBL396350 | 0.98 | — | — | |
| SCHEMBL4008535 | 0.98 | — | — | |
| Bromide SCHEMBL1397996 | 0.96 | HRH4 (0.40) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| Bromide SCHEMBL4608777 | 0.96 | HRH4 (0.40) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| SCHEMBL14900011 | 0.82 | DPP4 (0.35) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| SCHEMBL19187383 | 0.82 | DPP4 (0.35) | HRH4HRH3ALDH1A1LMNAAPEX1 | |
| Choline SCHEMBL27844516 | 0.82 | MEN1 (0.34) | HRH4HRH3ALDH1A1LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | claimed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240165082-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | TSP THERAPEUTICS INC. | 2024-05-23 | — | — | US | claimed |
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | claimed |
| EP-2419099-A2 | COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE | Epicept Corporation (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010120649-A2 | COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDROCHLORIDE FOR THE REDUCTION OF OXYGEN RADICAL FORMATION | EPICEPT CORPORATION (US) | 2010-10-21 | — | — | WO | claimed |
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240165082-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | TSP THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4340838-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | Paz, Alberto (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022245650-A1 | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT | PAZ ALBERTO (US) | 2022-11-24 | — | — | WO | disclosed |
| US-6166060-A | 1H-4(5)-substituted imidazole derivatives | GLIATECH, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0841922-A4 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH INC (US) | 1999-03-10 | — | — | EP | disclosed |
| CN-1192144-A | 1H-4(5)-substituted imidazole derivatives | GLIATECH INC (US) | 1998-09-02 | — | — | CN | disclosed |
| EP-0841922-A1 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1996038142-A1 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES | GLIATECH, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5162541-A | Using palladium containing catalysts and a hydrogen donor | SCHERING CORPORATION (US) | 1992-11-10 | — | — | US | disclosed |